Tbio NOC2L Nucleolar complex protein 2 homolog

Protein Summary

Description

Acts as an inhibitor of histone acetyltransferase activity; prevents acetylation of all core histones by the EP300/p300 histone acetyltransferase at p53/TP53-regulated target promoters in a histone deacetylases (HDAC)-independent manner. Acts as a transcription corepressor of p53/TP53- and TP63-mediated transactivation of the p21/CDKN1A promoter. Involved in the regulation of p53/TP53-dependent apoptosis. Associates together with TP63 isoform TA*-gamma to the p21/CDKN1A promoter. Histone modification by histone acetyltransferases (HAT) and histone deacetylases (HDAC) can control major aspects of transcriptional regulation. NOC2L represents a novel HDAC-independent inhibitor of histone acetyltransferase (INHAT) (Hublitz et al., 2005 [PubMed 16322561]).[supplied by OMIM, Mar 2008]

Uniprot Accession IDs

• Q9Y3T9
• Q5SVA3
• Q9BTN6
• Protein NOC2 homolog

Gene Name

• NOC2L

Ensembl ID

• ENST00000327044
• ENSP00000317992
• ENSG00000188976

Symbol

• NIR
• NIR
• NET7
• NET15
• PPP1R112

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
kinase perturbation	0.95
biological process	0.92
ligand (protein) perturbation	0.83
interacting protein	0.77
drug perturbation	0.71

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 574.17   (req: < 5)

Gene RIFs: 5   (req: <= 3)

Antibodies: 106   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 574.17   (req: >= 5)

Gene RIFs: 5   (req: > 3)

Antibodies: 106   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 15

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0